☰

Matthew A. Seager, Ph.D. - Publications

Affiliations: 
2005-2009 Merck & Co., Inc. 
 2009-2014 Bristol-Myers Squibb Company, New York, NY, United States 
 2017- Yale University, New Haven, CT 
Area:
Alzheimer's disease, schizophrenia, depression, learning, memory, cognition, drugs of abuse, hippocampus
Website:
http://www.linkedin.com/in/matthewseager
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

17/35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM. Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278. PMID 30543903 DOI: 10.1016/J.Bbr.2018.12.019  0.438
2016 Higgins MA, Marcin LR, Christopher Zusi F, Gentles R, Ding M, Pearce BC, Easton A, Kostich WA, Seager MA, Bourin C, Bristow LJ, Johnson KA, Miller R, Hogan J, Whiterock V, et al. Triazolopyridine ethers as potent, orally active mGlu2 positive allosteric modulators for treating schizophrenia. Bioorganic & Medicinal Chemistry. PMID 27914948 DOI: 10.1016/J.Bmc.2016.11.018  0.303
2011 Kuduk SD, Chang RK, Di Marco CN, Pitts DR, Greshock TJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT, Ray WJ. Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. Journal of Medicinal Chemistry. 54: 4773-80. PMID 21682298 DOI: 10.1021/Jm200400M  0.3
2009 Ma L, Seager MA, Seager M, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proceedings of the National Academy of Sciences of the United States of America. 106: 15950-5. PMID 19717450 DOI: 10.1073/Pnas.0900903106  0.333
2005 Asaka Y, Mauldin KN, Griffin AL, Seager MA, Shurell E, Berry SD. Nonpharmacological amelioration of age-related learning deficits: the impact of hippocampal theta-triggered training. Proceedings of the National Academy of Sciences of the United States of America. 102: 13284-8. PMID 16150707 DOI: 10.1073/Pnas.0506515102  0.611
2005 Seager MA, Barth VN, Phebus LA, Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology. 181: 126-33. PMID 15719213 DOI: 10.1007/S00213-005-2198-2  0.468
2005 Rasmussen K, Martin H, Berger JE, Seager MA. The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology. 48: 173-80. PMID 15695156 DOI: 10.1016/J.Neuropharm.2004.09.010  0.448
2004 Huff KD, Asaka Y, Griffin AL, Berg WP, Seager MA, Berry SD. Differential mastication kinematics of the rabbit in response to food and water: implications for conditioned movement. Integrative Physiological and Behavioral Science : the Official Journal of the Pavlovian Society. 39: 16-23. PMID 15379379 DOI: 10.1007/Bf02734253  0.669
2004 Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biological Psychiatry. 55: 1103-9. PMID 15158430 DOI: 10.1016/J.Biopsych.2004.02.012  0.475
2003 Seager MA, Smith-Bell CA, Schreurs BG. Conditioning-specific reflex modification of the rabbit (Oryctolagus cuniculus) nictitating membrane response: US intensity effects. Learning & Behavior. 31: 292-8. PMID 14577552 DOI: 10.3758/Bf03195990  0.611
2002 Seager MA, Johnson LD, Chabot ES, Asaka Y, Berry SD. Oscillatory brain states and learning: Impact of hippocampal theta-contingent training. Proceedings of the National Academy of Sciences of the United States of America. 99: 1616-20. PMID 11818559 DOI: 10.1073/Pnas.032662099  0.639
2001 Berry SD, Seager MA. Hippocampal theta oscillations and classical conditioning. Neurobiology of Learning and Memory. 76: 298-313. PMID 11726239 DOI: 10.1006/Nlme.2001.4025  0.619
2001 Buck DL, Seager MA, Schreurs BG. Conditioning-specific reflex modification of the rabbit (Oryctolagus cuniculus) nictitating membrane response: generality and nature of the phenomenon. Behavioral Neuroscience. 115: 1039-47. PMID 11584916 DOI: 10.1037//0735-7044.115.5.1039  0.609
2000 Asaka Y, Seager MA, Griffin AL, Berry SD. Medial septal microinfusion of scopolamine disrupts hippocampal activity and trace jaw movement conditioning. Behavioral Neuroscience. 114: 1068-77. PMID 11142639 DOI: 10.1037//0735-7044.114.6.1068  0.712
1999 Seager MA, Asaka Y, Berry SD. Scopolamine disruption of behavioral and hippocampal responses in appetitive trace classical conditioning. Behavioural Brain Research. 100: 143-51. PMID 10212061 DOI: 10.1016/S0166-4328(98)00123-5  0.642
1998 Seager MA, Borgnis RL, Berry SD. Hippocampal age differences reoccur after modification of stimulus configurations in rabbit jaw movement conditioning. Neurobiology of Aging. 19: 277-81. PMID 9662004 DOI: 10.1016/S0197-4580(98)00061-X  0.644
1997 Seager MA, Borgnis RL, Berry SD. Delayed acquisition of behavioral and hippocampal responses during jaw movement conditioning in aging rabbits. Neurobiology of Aging. 18: 631-9. PMID 9461061 DOI: 10.1016/S0197-4580(97)00160-7  0.649
Low-probability matches (unlikely to be authored by this person)
2018 Beshore DC, N Di Marco C, Chang RK, Greshock TJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Fuerst J, Hartman GD, Bilodeau MT, Ray WJ, Kuduk SD. MK-7622: A First-in-Class M Positive Allosteric Modulator Development Candidate. Acs Medicinal Chemistry Letters. 9: 652-656. PMID 30034595 DOI: 10.1021/Acsmedchemlett.8B00095  0.285
2010 Kuduk SD, Chang RK, Di Marco CN, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators. Acs Medicinal Chemistry Letters. 1: 263-7. PMID 24900206 DOI: 10.1021/Ml100095K  0.28
2012 Kuduk SD, Chang RK, Greshock TJ, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Identification of amides as carboxylic Acid surrogates for quinolizidinone-based m1 positive allosteric modulators. Acs Medicinal Chemistry Letters. 3: 1070-4. PMID 24900430 DOI: 10.1021/Ml300280G  0.278
2014 Yang ZQ, Shu Y, Ma L, Wittmann M, Ray WJ, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT, Kuduk SD. Discovery of naphthyl-fused 5-membered lactams as a new class of m1 positive allosteric modulators. Acs Medicinal Chemistry Letters. 5: 604-8. PMID 24900888 DOI: 10.1021/Ml500055H  0.276
2010 Zhao WQ, Santini F, Breese R, Ross D, Zhang XD, Stone DJ, Ferrer M, Townsend M, Wolfe AL, Seager MA, Kinney GG, Shughrue PJ, Ray WJ. Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. The Journal of Biological Chemistry. 285: 7619-32. PMID 20032460 DOI: 10.1074/Jbc.M109.057182  0.265
2015 Li YW, Seager MA, Wojcik T, Heman K, Molski TF, Fernandes A, Langdon S, Pendri A, Gerritz S, Tian Y, Hong Y, Gallagher L, Merritt JR, Zhang C, Westphal R, et al. Biochemical and Behavioral Effects of PDE10A inhibitors: Relationship to Target Site Occupancy. Neuropharmacology. PMID 26522433 DOI: 10.1016/J.Neuropharm.2015.10.037  0.261
2008 Ray WJ, Seager M, Ma L, Wittmann M, Getty K, Marlatt M, Crouthamel M, Wu G, Sankaranarayananan S, Simon A, Burno M, Jones K, Graufields VK, Bickel D, Posavec D, et al. P4-305: Allosteric potentiation of the M1 muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treatment of Alzheimer's disease Alzheimer's & Dementia. 4: T761-T761. DOI: 10.1016/J.Jalz.2008.05.2375  0.258
2011 Kuduk SD, Chang RK, Di Marco CN, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series. Bioorganic & Medicinal Chemistry Letters. 21: 1710-5. PMID 21324684 DOI: 10.1016/J.Bmcl.2011.01.094  0.246
2010 Kuduk SD, Di Marco CN, Chang RK, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Heterocyclic fused pyridone carboxylic acid M(1) positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20: 2533-7. PMID 20303264 DOI: 10.1016/J.Bmcl.2010.02.096  0.245
2010 Yang FV, Shipe WD, Bunda JL, Nolt MB, Wisnoski DD, Zhao Z, Barrow JC, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Hartman GD, Lindsley CW. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M(1) positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20: 531-6. PMID 20004574 DOI: 10.1016/J.Bmcl.2009.11.100  0.244
2010 Kuduk SD, Di Marco CN, Cofre V, Pitts DR, Ray WJ, Ma L, Wittmann M, Veng L, Seager MA, Koeplinger K, Thompson CD, Hartman GD, Bilodeau MT. N-heterocyclic derived M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20: 1334-7. PMID 20097564 DOI: 10.1016/J.Bmcl.2010.01.013  0.244
2010 Kuduk SD, Di Marco CN, Cofre V, Pitts DR, Ray WJ, Ma L, Wittmann M, Seager MA, Seager M, Koeplinger K, Thompson CD, Hartman GD, Bilodeau MT. Pyridine containing M(1) positive allosteric modulators with reduced plasma protein binding. Bioorganic & Medicinal Chemistry Letters. 20: 657-61. PMID 19962304 DOI: 10.1016/J.Bmcl.2009.11.059  0.241
2011 Kuduk SD, Di Marco CN, Cofre V, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Fused heterocyclic M1 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 21: 2769-72. PMID 21055928 DOI: 10.1016/J.Bmcl.2010.10.028  0.237
2010 Kuduk SD, DiPardo RM, Beshore DC, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT. Hydroxy cycloalkyl fused pyridone carboxylic acid M(1) positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. 20: 2538-41. PMID 20346667 DOI: 10.1016/J.Bmcl.2010.02.095  0.227
2010 Kuduk SD, Di Marco CN, Cofre V, Pitts DR, Ray WJ, Ma L, Wittmann M, Seager MA, Koeplinger K, Thompson CD, Hartman GD, Bilodeau MT. Corrigendum to "Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding" [Bioorg. Med. Chem. Lett. 20 (2010) 657] (DOI:10.1016/j.bmcl.2009.11.059) Bioorganic and Medicinal Chemistry Letters. 20: 1796. DOI: 10.1016/J.Bmcl.2010.01.027  0.219
2008 Savage MJ, McCampbell AR, Wessner K, Na S, Marlatt M, Bickel D, Burno M, Jones K, Kuzmick-Graufelds V, Yeh S, Zhang R, White R, Seager M, Majercak J, Ray WJ. P1-016: Dietary induction of hyperhomocystemia and the impact on Alzheimer's disease-relevant markers Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.601  0.21
2009 Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, Regan C, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, (15950-15955) DOI: 10.1073/pnas.0900903106) Proceedings of the National Academy of Sciences of the United States of America. 106: 18040. DOI: 10.1073/pnas.0910597106  0.105
1969 Wilcox CF, Seager MA. Cleavage of hindered aromatic ethers. Kinetics Journal of Organic Chemistry. 34: 2319-2323.  0.01
Hide low-probability matches.